Share price has ticked higher this morning but on low volumes so far. Buy side looking a bit more healthier but there is one annoying shareholder who keeps filling the gap downwards on small volumes despite the increased strength on the buy side. Should be an interesting few weeks as PIQ have stated they intend to update the market on all 3 of their other major tests, namely endo, Esophageal cancer and Oxidix, before the end of the December quarter. I also note that the short position in PIQ has dropped slightly to circa 731k shares in the past week. Assuming the test results updates are positive and PIQ meet their stated aim of commencing first commercial sales of PromarkerD in the March quarter, the next 6 months or so should be very interesting for us as shareholders.
PIQ Price at posting:
67.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)